


YHO-13351 free base

Chemical Properties

CAS No. :	912288-64-3
Formula:	C ₂₆ H ₃₃ N ₃ O ₄ S
Molecular Weight:	483.62
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	YHO-13351 free base, the water-soluble prodrug of YHO-13177, is an inhibitor of BCRP (breast cancer resistance protein).
Targets(IC50)	BCRP
In vivo	In mice, YHO-13351 was rapidly converted into YHO-13177 after its oral or intravenous administration. Coadministration of Irinotecan Hydrochloride with YHO-13351 significantly increased the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas Irinotecan Hydrochloride alone had little effect in these tumor models[1].

Solubility Information

Solubility	DMSO: 90 mg/mL (186.1 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.82 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0677 mL	10.3387 mL	20.6774 mL
5 mM	0.4135 mL	2.0677 mL	4.1355 mL
10 mM	0.2068 mL	1.0339 mL	2.0677 mL
50 mM	0.0414 mL	0.2068 mL	0.4135 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Yamazaki R, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. *Mol Cancer Ther.* 2011 Jul;10(7):1252-63.

Shishido Y, et al. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. *Anticancer Res.* 2013 Apr;33(4):1379-86.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481